Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 18, 2005

View Archived Issues

CYT006-AngQb: preclinical validation and further study in healthy volunteers

Novel lactam sodium channel blocker displays anticonvulsant activity

sanofi -aventis profiles pipeline development

Pfizer's new nNOS inhibitors demonstrate efficacy for pain and stroke

Antidepressant effects of two new triple reuptake inhibitors

Preclinical efficacy of FG-3019 against diabetes-associated metabolic/cardiovascular complications

Good safety and pharmacokinetic data reported for ANA-975 in monkeys and humans

Clinical evidence supports the use of CpG-10101 in hepatitis C

Gilead and Roche settle Tamiflu dispute

Johnson & Johnson and Guidant amend acquisition agreement

ev3 and Micro Therapeutics announce merger agreement

Medarex anticipates milestone payment from Bristol-Myers Squibb

Phase II study evaluates TroVax with IL-2 for metastatic renal cell carcinoma

Pivotal Veronate phase III study completes enrollment

Abraxane licensed to Taiho for Japan

Xenome begins phase I/II study for XEN-2174 for severe intractable pain

SNS-595 studied for refractory acute leukemia in phase I trial

Cardioprotective effects of a new plasminogen activator inhibitor

Reverse D-4F: potential in atherosclerosis

Anticancer potential of novel chalcones

AC-260584: an atypical M1 agonist with an ectopic binding site

ABT-127: Abbott's new D3 receptor antagonist targeted as an antipsychotic

Enhanced antitumor activity with IMC-3G3 plus doxorubicin in a leiomyosarcoma model

GNS-037: A novel HCV entry inhibitor

Novel HERG channel activator NS-1643 under investigation for treatment of arrhythmias

Shanghai Sunway Biotech's H101 approved for refractory nasopharyngeal cancer

Recent CNRS patent discloses novel MRI agents

Recent patents disclose novel agents for the treatment of endocrine-related disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...